Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity Inc. stock logo
CELC
Celcuity
$10.86
+0.4%
$10.14
$7.58
$19.77
$410.93M0.56299,087 shs207,917 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$9.56
+12.2%
$6.10
$3.99
$9.70
$434.48M2.22942,033 shs3.10 million shs
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$3.36
-4.0%
$3.48
$2.62
$12.50
$348.13M0.8253,303 shs8,278 shs
Exagen Inc. stock logo
XGN
Exagen
$5.82
+3.4%
$4.70
$1.67
$7.20
$104.77M1.5108,754 shs107,507 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity Inc. stock logo
CELC
Celcuity
+0.37%+6.59%+11.38%-13.95%-35.70%
LifeMD, Inc. stock logo
LFMD
LifeMD
+12.21%+18.98%+86.35%+31.50%+5.29%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
-4.00%+5.00%-19.81%-34.12%+335,999,900.00%
Exagen Inc. stock logo
XGN
Exagen
+3.37%-14.79%+26.52%+36.30%+230.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celcuity Inc. stock logo
CELC
Celcuity
1.9148 of 5 stars
3.61.00.00.02.52.50.0
LifeMD, Inc. stock logo
LFMD
LifeMD
1.9345 of 5 stars
2.54.00.00.02.41.70.6
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/AN/AN/AN/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
4.4078 of 5 stars
3.53.00.04.52.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity Inc. stock logo
CELC
Celcuity
3.14
Buy$30.17177.78% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$11.0015.06% Upside
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
0.00
N/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$8.0037.46% Upside

Current Analyst Ratings Breakdown

Latest XGN, CELC, LFMD, and SBC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Exagen Inc. stock logo
XGN
Exagen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/7/2025
Exagen Inc. stock logo
XGN
Exagen
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/30/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/11/2025
Celcuity Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
3/12/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $14.00
3/12/2025
Exagen Inc. stock logo
XGN
Exagen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$15.00 ➝ $15.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$5.48 per shareN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
$234.01M1.86N/AN/A$0.15 per share63.73
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$205.42M1.69$0.07 per share49.20($1.68) per share-2.00
Exagen Inc. stock logo
XGN
Exagen
$56.72M1.85N/AN/A$1.33 per share4.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity Inc. stock logo
CELC
Celcuity
-$63.78M-$2.81N/AN/AN/AN/A-62.66%-39.78%N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.34N/A79.67N/A-12.06%N/A-36.34%N/A
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$340KN/A0.000.60N/AN/A-11.59%-7.05%6/17/2025 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$0.84N/AN/AN/A-30.36%-92.58%-33.74%N/A

Latest XGN, CELC, LFMD, and SBC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
5/12/2025Q1 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million
5/6/2025Q1 2025
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04$0.01+$0.05$0.01$62.47 million$65.70 million
3/31/2025Q4 2024
Celcuity Inc. stock logo
CELC
Celcuity
-$0.72-$0.85-$0.13-$0.85N/AN/A
3/28/2025Q4 2024
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$0.17$0.18+$0.01$0.06$56.34 million$57.90 million
3/10/2025Q4 2024
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04-$0.02+$0.02-$0.02$57.43 million$64.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity Inc. stock logo
CELC
Celcuity
0.65
10.35
10.36
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.83
0.78
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
0.06
2.79
2.76
Exagen Inc. stock logo
XGN
Exagen
1.54
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
Celcuity Inc. stock logo
CELC
Celcuity
63.33%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
60.82%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Celcuity Inc. stock logo
CELC
Celcuity
15.77%
LifeMD, Inc. stock logo
LFMD
LifeMD
15.97%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
63.90%
Exagen Inc. stock logo
XGN
Exagen
26.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity Inc. stock logo
CELC
Celcuity
4037.84 million31.27 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23045.45 million36.40 millionOptionable
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/A103.61 million37.19 millionN/A
Exagen Inc. stock logo
XGN
Exagen
22018.00 million13.03 millionOptionable

Recent News About These Companies

William Blair Issues Negative Outlook for Exagen Earnings
Equities Analysts Set Expectations for Exagen Q1 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celcuity stock logo

Celcuity NASDAQ:CELC

$10.86 +0.04 (+0.37%)
As of 05/14/2025 04:00 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$9.56 +1.04 (+12.21%)
As of 05/14/2025 04:00 PM Eastern

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

SBC Medical Group stock logo

SBC Medical Group NASDAQ:SBC

$3.36 -0.14 (-4.00%)
As of 05/14/2025 03:27 PM Eastern

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.

Exagen stock logo

Exagen NASDAQ:XGN

$5.82 +0.19 (+3.37%)
As of 05/14/2025 04:00 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.